Guidea acquired by Invene to expand AI healthcare capabilities

Healthcare-focused engineering and AI solutions company Invene has acquired Guidea – a product design consultancy. The acquisition will expand Invene’s capabilities beyond software engineering to expand into a full-stack innovation partner, supporting the next generation of AI-driven healthcare products from blueprint to build.

The acquisition will see Guidea  – which launched Femovate as a women’s health incubator in 2022, investing nearly US$2m in services into femtech startups – combine its strengths in product strategy, clinical-grade UX, and systems thinking with Invene’s capabilities in AI, engineering, and compliance to offer blueprint-to-build support for digital health, diagnostics, medtech, and biopharma innovators.

“AI in healthcare can’t just be powerful – it has to be usable, compliant, and commercially viable,” said James Griffin, Founder and CEO of Invene.

“Guidea brings the upstream clarity and clinical insight that helps us de-risk what gets built. Together, we’re helping mid-market and enterprise teams turn bold ideas into working AI products with measurable impact.”

The integration advances Invene’s evolution from an engineering services provider to a strategic partner for healthcare and life sciences enterprises navigating the complexity of AI, compliance, and clinical adoption. The combined team offers end-to-end capabilities, including R&D strategy, clinical-grade UX design, AI implementation, and product commercialisation, tailored to regulated healthcare environments.

“The next phase of healthcare innovation will be shaped by AI, and success will depend on clear product strategy, strong clinical and market validation, and experienced execution,” said Theresa Neil, who joins Invene as chief product officer.

“By combining deep domain expertise with engineering excellence in R&D, we can build AI solutions that actually work in practice.”

The acquisition also enhances Invene’s ability to serve biopharma, diagnostics, and digital health clients seeking integrated support for clinical-grade innovation.